Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track RGNX with free AI briefings, catalyst countdowns, and dilution alerts.

RGNX · REGENXBIO Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$290M Cash, Pro Forma
73.6mo Cash Runway
16.3% Short Interest
$21.4 Analyst Target (10)
Follow RGNX by email Get an email when RGNX reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about RGNX, unsubscribe in one click. Privacy

📣 What RGNX Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Local Steroid Neovascular Age-Related Macular Degeneration (nAMD) Phase 2 · NCT04514653 Active not recruiting
Topical Steroid Neovascular Age-Related Macular Degeneration (nAMD) Phase 2 · NCT04514653 Active not recruiting
Single intravenous (IV) dose of human Low… Homozygous Familial Hypercholesterolemia (HoFH) N/A · NCT04080050 Unknown

Also used in these trials (approved or third-party drugs, not RGNX's own candidates): Aflibercept, Ranibizumab.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

RGNX had $251M in cash and short-term investments on its Sep 30, 2026 balance sheet. Including the cash events since then, it holds about $290M pro forma, before operating spending after that date:

It burns about $11.8M/quarter from operations, an estimated runway of 73.6 months from Sep 30, 2026 at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 54 · Elevated

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when RGNX files for a raise →

👥 Who Owns RGNX

Insiders 7.3% Institutions (237 holders) 65.3% Public and other holders 27.4%
HolderTypeShares% of sharesAs of
Blackrock Inc. Institution (13F) 7,676,594 11.61% 2026-09-30
Redmile Group, LLC Institution (13F) 5,048,502 7.64% 2026-09-30
JPMORGAN CHASE & CO. Institution (13G, 5%+) 3,560,915 5.39% 2026-09-30
State Street Corporation Institution (13F) 3,153,336 4.77% 2026-09-30
Allan M. Fox
Director · +86,415 options
Insider 2,911,327 4.40% 2026-05-29
Vanguard Portfolio Management LLC Institution (13F) 2,646,375 4.00% 2026-09-30
Vanguard Capital Management LLC Institution (13F) 2,522,986 3.82% 2026-09-30
Price (T.Rowe) Associates Inc Institution (13F) 1,929,442 2.92% 2026-09-30
Two Sigma Investments, LP Institution (13F) 1,899,761 2.87% 2026-09-30
Morgan Stanley Institution (13F) 1,814,239 2.74% 2026-09-30
Goldman Sachs Group Inc Institution (13F) 1,681,187 2.54% 2026-09-30
Geode Capital Management, LLC Institution (13F) 1,582,758 2.39% 2026-09-30

Share count 66,122,600 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📈 Recent Insider Activity (Form 4)

Trade dateInsiderTransactionSharesPriceOwned after
2026-11-01
filed 2026-11-03
Christmas Patrick J.
Award (A) 34,722 – 240,690
2026-11-01
filed 2026-11-03
PAKOLA STEVE
Award (A) 34,722 – 240,263
2026-11-01
filed 2026-11-03
Chan Mitchell
Award (A) 24,305 – 147,120
2026-11-01
filed 2026-11-03
Malzahn Craig
Award (A) 27,777 – 109,737
2026-09-01
filed 2026-09-03
Chan Mitchell
Tax withholding (F) 4,902 $9.32 122,815

Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.

📅 Past FDA Decisions & Stock Reactions

DateDrugTypeRun-up 30dDecision 1dAfter 5d
2026-02-08 RGX-121 BLA -32.2% -0.2% -22.7%

Browse all historical PDUFA outcomes →

Get the full RGNX picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for RGNX and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.